TaiDoc (4736) reported revenue of NT$439.9 million for Oct 2026, +53.9% year on year and +10.4% from the previous month. Revenue for Jan–Oct 2026 was NT$3.73 billion (+7.9% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 20 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$439.9 million | +53.9% | +10.4% |
| Sep 2026 | NT$398.4 million | +7.1% | +0.3% |
| Aug 2026 | NT$397.2 million | +42.7% | +5.5% |
| Jul 2026 | NT$376.6 million | -11.9% | +4.6% |
| Jun 2026 | NT$360.2 million | +2.1% | +12.8% |
| May 2026 | NT$319.2 million | -15.0% | -13.3% |
| Apr 2026 | NT$368.2 million | -6.2% | -17.1% |
| Mar 2026 | NT$444.1 million | +48.7% | +69.4% |
| Feb 2026 | NT$262.1 million | -15.6% | -28.8% |
| Jan 2026 | NT$368.2 million | +0.2% | -9.7% |
| Dec 2025 | NT$407.7 million | +6.3% | +21.8% |
| Nov 2025 | NT$334.8 million | -13.9% | +17.2% |
| Oct 2025 | NT$285.8 million | -27.6% | -23.2% |
| Sep 2025 | NT$372.1 million | -15.8% | +33.7% |
| Aug 2025 | NT$278.4 million | -26.0% | -34.9% |
| Jul 2025 | NT$427.6 million | +3.2% | +21.2% |
| Jun 2025 | NT$352.8 million | -9.8% | -6.1% |
| May 2025 | NT$375.7 million | -1.1% | -4.3% |
| Apr 2025 | NT$392.5 million | +0.0% | +31.4% |
| Mar 2025 | NT$298.7 million | -19.8% | -3.9% |
| Feb 2025 | NT$310.7 million | +8.6% | -15.4% |
| Jan 2025 | NT$367.4 million | -12.5% | -4.2% |
| Dec 2024 | NT$383.6 million | +14.4% | -1.3% |
| Nov 2024 | NT$388.7 million | +9.4% | -1.5% |
| Oct 2024 | NT$394.9 million | +1.8% | -10.6% |
Jan–Oct 2026 cumulative: NT$3.73 billion (+7.9% YoY)
Other Biotech & Medical companies
Compare with peers: TaiDoc vs PEC / TaiDoc vs Lotus Pharm / TaiDoc vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
因多參數量測儀及試片出貨量增加
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16